Neurofilament light chain truncation and uses thereof

By designing the specific amino acid sequence of the neurofilament light chain truncated body, the problem of poor protein stability in the prior art is solved, and high-purity and high-stability antigens are provided, which are used for the early diagnosis of Alzheimer's disease, significantly improving The stability and yield of diagnostic markers were achieved.

CN118955678APending Publication Date: 2024-11-15BEIJING INST OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411044700.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The current commercially available human neurofilament light chain full-length protein has poor stability, easy precipitation, and low concentration, which cannot meet the clinical needs of early diagnosis of Alzheimer's disease.

Method used

Provide a neurofilament light chain truncated body whose sequence contains specific amino acid sequences, which are used in the form of nucleic acid molecules, expression vectors and host cells to prepare antigens, which improves the stability and purity of proteins, and is suitable for Alzhei Early diagnosis of Silence.

Benefits of technology

The neurofilament light chain truncate has excellent stable performance, high antigen signal, and the identification concentration is consistent with the detection results, which significantly improves the stability and yield of the marker NFL, a marker for early diagnosis of Alzheimer's blood.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure HDA0004974639530000011
    Figure HDA0004974639530000011
  • Figure HDA0004974639530000012
    Figure HDA0004974639530000012
Patent Text Reader

Abstract

The invention provides a neurofilament light chain truncation and application thereof, the sequence of the neurofilament light chain truncation comprises a sequence as shown in SEQ ID NO: 2 or 3 or a sequence as shown in SEQ ID NO: 2 or 3, the neurofilament light chain truncation is good in stability, and compared with a commercial antigen, the neurofilament light chain truncation is relatively high in antigen signal and relatively high in sensitivity. The marker concentration is consistent with the detection result, the performance is excellent, and the kit can be used for AD blood early diagnosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of protein engineering technology, and in particular to a neurofilament light chain truncate and use thereof. Background Art

[0002] Neurofilament light chain (NFL) is a cytoskeletal protein that is only expressed in neurons. It is mainly present in axons and is involved in a variety of life activities, such as axon diameter regulation, axon transport, negative regulation of neuronal apoptosis, and cerebral cortex development. NFL will break and enter the cerebrospinal fluid and blood after neuronal damage. The content of NFL in the blood is generally considered to be related to neuronal damage. The level of NFL gradually increases with the progression of Alzheimer's Disease (AD), and the signal is stronger in the late stage reflecting neurodegeneration. In addition, in familial AD, the patient's blood NFL level increased significantly 16 years before the onset of clinical symptoms, indicating that its blood abundance can be used as a criterion for early diagnosis of AD.

[0003] However, the full-length human NFL protein currently available on the market has poor stability, is easy to precipitate, and has low concentration, and cannot meet the clinical requirements for early detection. Summary of the invention

[0004] In response to the technical problems existing in the prior art, the present application provides a neurofilament light chain truncate and its application. The neurofilament light chain truncate has good stability and high purity, and can greatly improve the stability and yield of NFL, an early diagnostic marker for Alzheimer's disease in the blood.

[0005] The specific technical solutions of this application are as follows:

[0006] 1. A neurofilament light chain truncate, wherein the sequence of the neurofilament light chain truncate comprises the sequence shown in SEQ ID NO: 2 or 3 or the sequence shown in SEQ ID NO: 2 or 3.

[0007] 2. A nucleic acid molecule comprising a nucleic acid encoding the neurofilament light chain truncation described in item 1.

[0008] 3. The nucleic acid molecule according to item 1, wherein the nucleic acid molecule comprises the sequence shown in any one of SEQ ID NOs: 4-5 or the sequence shown in any one of SEQ ID NOs: 4-5.

[0009] 4. An expression vector comprising the nucleic acid molecule described in item 2 or 3.

[0010] 5. The expression vector according to item 4, wherein the expression vector is a plasmid, a cosmid, a phage or a viral vector, preferably a plasmid.

[0011] 6. A host cell comprising the expression vector described in item 4 or 5;

[0012] Preferably, the host cell is a eukaryotic cell, a prokaryotic cell or a bacterial cell, preferably a prokaryotic cell, and more preferably Escherichia coli.

[0013] 7. Use of the neurofilament light chain truncate described in Item 1, the nucleic acid molecule described in Item 2 or 3, the expression vector described in Item 4 or 5, or the host cell described in Item 6 in preparing an antigen.

[0014] 8. Use of the neurofilament light chain truncated form of item 1, the nucleic acid molecule of item 2 or 3, the expression vector of item 4 or 5, or the host cell of item 6 in detecting Alzheimer's disease;

[0015] Or use in the preparation of an Alzheimer's disease diagnostic preparation or diagnostic kit.

[0016] 9. A preparation for detecting Alzheimer's disease, comprising the neurofilament light chain truncate described in Item 1, the nucleic acid molecule described in Item 2 or 3, the expression vector described in Item 4 or 5, or the host cell described in Item 6.

[0017] 10. The preparation according to item 9, further comprising a pharmaceutically acceptable excipient.

[0018] 11. Use of the neurofilament light chain truncate described in Item 1, the nucleic acid molecule described in Item 2 or 3, the expression vector described in Item 4 or 5, or the host cell described in Item 6 as an antigen in the preparation of antibodies for preventing or treating Alzheimer's disease.

[0019] 12. An antibody prepared by immunization using the neurofilament light chain truncated form of item 1, the nucleic acid molecule of item 2 or 3, the expression vector of item 4 or 5, or the host cell of item 6.

[0020] Effects of the Invention

[0021] The neurofilament light chain truncate described in the present application has good stability, and compared with commercial antigens, its antigen signal is relatively high, and its labeled concentration is consistent with the test result, with excellent performance, and can be used for early diagnosis of AD blood. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 Schematic diagram of electrophoresis of NFL, where A is the electrophoresis diagram of natural NFL and B is the electrophoresis diagram of NFL truncated form.

[0023] Figure 2 Schematic diagram of the stability of NFL truncations.

[0024] Figure 3 Schematic diagram of ELISA for NFL truncations and commercial antigens.

[0025] Figure 4 This is a schematic diagram of the standard curve for measuring standards using the Simoa method. DETAILED DESCRIPTION

[0026] The present application is described in detail below in conjunction with the described embodiments. Although specific embodiments of the present application are shown, it should be understood that the present application can be implemented in various forms and should not be limited by the embodiments set forth herein. On the contrary, these embodiments are provided to enable a more thorough understanding of the present application and to enable the scope of the present application to be fully communicated to those skilled in the art.

[0027] It should be noted that certain words are used in the specification and claims to refer to specific components. Those skilled in the art should understand that technicians may use different nouns to refer to the same component. This specification and claims do not use the difference in nouns as a way to distinguish components, but use the functional differences of components as the criterion for distinction. As mentioned throughout the specification and claims, "including" or "comprising" are open-ended terms and should be interpreted as "including but not limited to". The subsequent description of the specification is a preferred embodiment of the present application, but the description is based on the general principles of the specification and is not intended to limit the scope of the present application. The scope of protection of the present application shall be determined by the attached claims.

[0028] definition

[0029] As used herein, the term "neurofilament light chain" refers to "human neurofilament light chain" and encompasses all genetically encoded isoforms or variants, as well as species thereof that are C-terminally truncated in vivo, N-terminally truncated in vivo, N-terminally truncated and C-terminally truncated in vivo, post-translationally modified in vivo, or any combination thereof. The terms "neurofilament light chain", "neurofilament light polypeptide" and "NFL" are used interchangeably herein. Full-length NFL has the amino acid sequence of SEQ ID NO: 1, and the sequence of SEQ ID NO: 1 is as follows:

[0030] MSSFSYEPYYSTSYKRRYVETPRVHISSVRSGYSTARSAYSSYSAPVS

[0031] SSLSVRRSYSSSSSGSLMPSLENLDLSQVAAISNDLKSIRTQEKAQLQDLND

[0032] RFASFIERVHELEQQNKVLEAELLVLRQKHSEPSRFRALYEQEIRDLRLAA

[0033] EDATNEKQALQGEREGLEETLRNLQARYEEEVLSREDAEGRLMEARKG

[0034] ADEAALARAELEKRIDSLLMDEISFLKKVHEEEIAELQAQIQYAQISVEMD

[0035] VTKPDLSAALKDIRAQYEKLAAKNMQNAEEWFKSRFTVLTESAAKNTD

[0036] AVRAAKDEVSESRRLLKAKTLEIEACRGMNEALEKQLQELEDKQNADIS

[0037] AMQDTINKLENELRTTKSEMARYLKEYQDLLNVKMALDIEIAAYRKLLE

[0038] GEETRLSFTSVGSITSGYSQSSQVFGRSAYGGLQTSSYLMSTRSFPSYYTS

[0039] HVQEEQIEVEETIEAAKAEEAKDEPPSEGEAEEEEKDKEEAEEEEAAEEEE

[0040] AAKEESEEAKEEEEGGEGEEGEETKEAEEEEKKVEGAGEEQAAKKKD

[0041] As used herein, the term "antibody" refers to a molecule that is a member of a family of glycosylated proteins called immunoglobulins, which is capable of specifically binding to an antigen.

[0042] As used herein, the term "antigen" has been used to refer to an entity bound by an antibody or receptor, and has also been used to refer to an entity that can induce antibody production. More recent usage limits the meaning of antigen to an entity bound by an antibody or receptor.

[0043] As used herein, the "homology", "identity" and "similarity" refer to the sequence similarity between two nucleic acid molecules. "Homology", "identity" or "similarity" can be determined by comparing the positions in each sequence, and the sequences can be aligned for comparison purposes. When the equivalent position in the compared sequence is occupied by the same base, the molecules are identical at that position; when the equivalent site is occupied by the same or similar amino acid (e.g., similar in spatial properties or charged properties) residue, the molecules can be referred to as being homologous (similar) at that position. The expression of homology / similarity or identity percentage refers to a function of the number of identical or similar amino acids at the position shared by the compared sequences. "Unrelated" or "non-homologous" sequences share less than 40% identity, preferably less than 25% identity with the sequences of the present application. When comparing two sequences, the absence of residues (amino acids or nucleic acids) or the presence of extra residues also reduces identity and homology / similarity. In a specific embodiment, two or more sequences or subsequences are considered to be substantially or significantly homologous, similar or identical if their sequences are about 60%, or about 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical over a specified region, as determined using the BLAST or BLAST 2.0 sequence comparison algorithm with the default parameters described below or by manual alignment and visual inspection provided online by, for example, the National Center for Biotechnology Information (NCBI). This definition also relates to or can be used to test the complement of a sequence. Thus, to the extent permitted by the context of the present invention, for example, if the nucleotide sequence can be predicted to occur naturally in a DNA duplex, or can occur naturally in the form of one or both of the complementary strands, then the nucleotide sequence that is complementary to a specified target sequence or a variant thereof is itself considered to be "similar" to the target sequence, and when referring to "similar" nucleic acid sequences, single-stranded sequences, their complementary sequences, double-stranded strand complexes, sequences that can encode the same or similar polypeptide products, and any allowed variants of any of the above. Circumstances in which similarity must be limited to the analysis of a single nucleic acid strand sequence can include, for example, the detection and quantification of the expression of a specific RNA sequence or coding sequence in a cell. This definition also includes sequences with deletions and / or additions, as well as sequences with substitutions.In embodiments, the identity or similarity can be over a region that is at least about 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 10, 21, 22, 23, 24, 25, or more nucleotides in length, or over a region that is more than about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or more than about 100 nucleotides in length.

[0044] As used herein, the term "nucleotide" refers to naturally occurring nucleotides, as well as synthetic nucleotide analogs that are recognized by cellular enzymes.

[0045] As used herein, the term "expression vector" refers to any natural or artificially constructed expression vector containing a nucleic acid molecule, wherein the nucleic acid molecule can be catalyzed by a cellular transcriptase and / or translation enzyme. Exemplary expression vectors include: plasmids, viruses (including bacteriophages), cosmids, artificial chromosomes or transposons, etc. In some embodiments, the expression vector is a plasmid.

[0046] As used herein, the term "host cell" refers to any biological cell that can be cultured in a culture medium and used to express a recombinant gene. These host cells can be eukaryotic or prokaryotic cells, or microorganisms such as bacterial cells, or cells derived from a cell line (such as a mammalian immortal cell line), etc. In some embodiments, the host cell is a prokaryotic cell, such as Escherichia coli.

[0047] As used herein, the term "recombinant" refers to a nucleic acid molecule or polypeptide that is in a non-naturally occurring environment and is produced by human intervention.

[0048] As used herein, the term "treatment" refers to therapeutic treatment and preventive or preventive measures, wherein the purpose is to prevent or slow down (mitigate) undesirable physiological changes or diseases / disorders. Beneficial or desired clinical results include, but are not limited to, whether detectable or undetectable symptom alleviation, reduction of disease extent, stabilization of disease state (i.e., no deterioration), delay or slowing of disease progression, improvement or alleviation of disease state, and relief (whether partial relief or total relief). "Treatment" can also mean extended survival compared to the expected survival if not treated. Those in need of treatment include those who have already suffered from a disease, condition, or disorder, and those who are prone to a disease, condition, or disorder, or those in which a disease, condition, or disorder is to be prevented.

[0049] Neurofilament light chain truncations

[0050] The present application provides a neurofilament light chain truncate, wherein the sequence of the neurofilament light chain truncate comprises the sequence shown in SEQ ID NO: 2 or 3 or the sequence shown in SEQ ID NO: 2 or 3.

[0051] The sequence of SEQ ID NO:2 is as follows:

[0052] QLQDLNDRFASFIERVHELEQQNKVLEAELLVLRQKHSEPSRFRALY

[0053] EQEIRDLRLAAEDATNEKQALQGEREGLEETLRNLQARYEEEVLSREDAE

[0054] GRLMEARKGADEAALARAELEKRIDSLMDEISFLKKVHEEEIAELQAQIQ

[0055] YAQISVEMDVTKPDLSAALKDIRAQYEKLAAKNMQNAEEWFKSRFTVL

[0056] TESAAKNTDAVRAAKDEVSESRRLLKAKTLEIEACRGMNEALEKQLQEL

[0057] EDKQNADISAMQDTINKLENELRTTKSEMARYLKEYQDLLNVKMALDIE

[0058] IAAYRKLLEGE

[0059] The sequence of SEQ ID NO:3 is as follows:

[0060] GPHMQLQDLNDRFASFIERVHELEQQNKVLEAELLVLRQKHSEPSRFRALYEQEIRDLRLAAEDATNEKQALQGEREGLEETLRNLQARYEEEVLSREDAEGRLMEARKGADEAALARAELEKRIDSLMDEISFLKKVHEEEIAELQAQIQYAQ ISVEMDVTKPDLSAALKDIRAQYEKLAAKNMQNAEEWFKSRFTVLTESAAKNTDAVRAAKDEVSESRRLLKAKTLEIEACRGMNEALEKQLQELEDKQNADISAMQDTINKLENELRTTKSEMARYLKEYQDLLNVKMALDIEIAAYRKLLEGE

[0061] The sequence is a highly stable sequence obtained by rational design based on the natural amino acid sequence of neurofilament light chain.

[0062] In the present application, SEQ ID NO: 3 is obtained by adding GPHM to the 5' end of SEQ ID NO: 2. After the addition of GPHM, it has an obvious fit effect on the expression plasmid, which is beneficial to the antigen expression.

[0063] Those skilled in the art can also understand that the neurofilament light chain truncations are not limited to the specific sequences listed above. The sequences of the neurofilament light chain truncations should include sequences that contain one, two, or three or more mutations compared to the sequences shown in any one of SEQ ID NOs: 2-3, but are still substantially functionally identical to the sequences shown in any one of SEQ ID NOs: 2-3, and sequences that have 95%, 96%, 97%, 98%, or 99% sequence identity compared to the sequences shown in any one of SEQ ID NOs: 2-3.

[0064] Nucleic acid molecules, expression vectors and host cells

[0065] The present application provides a nucleic acid molecule comprising a sequence encoding the above-mentioned neurofilament light chain truncate. In some embodiments, the nucleic acid molecule comprises a sequence as shown in any one of SEQ ID NOs: 4-5 or a sequence as shown in any one of SEQ ID NOs: 4-5 or a sequence complementary to a sequence as shown in any one of SEQ ID NOs: 4-5.

[0066] In some embodiments, the nucleotide sequence encoding the above-mentioned neurofilament light chain truncate is codon optimized. Generally, codon optimization involves balancing the percentage of selected codons with the abundance of disclosed human transfer RNAs so that none of them is overloaded or limited. In some cases, this may be necessary because most amino acids are encoded by more than one codon, and codon usage varies from organism to organism. The codon usage difference between the transfected gene and the host cell may affect the protein expression and immunogenicity of the nucleic acid construct. Generally, for codon optimization, codons are selected to select those codons that are balanced with human usage frequency. Generally, the redundancy of amino acid codons makes different codons encode one amino acid. In some embodiments, when selecting a codon for replacement, the resulting mutation may be required to be a silent mutation so that the codon change does not affect the amino acid sequence. Generally, the last nucleotide of the codon can remain unchanged without affecting the amino acid sequence.

[0067] Wherein, SEQ ID NO:4 is used to encode the amino acid sequence shown in SEQ ID NO:2, and SEQ ID NO:5 is used to encode the amino acid sequence shown in SEQ ID NO:3, wherein the sequence of SEQ ID NO:4 is as follows:

[0068] CACAGCTGCAGGATCTGAATGATCGTTTTGCAAGTTTTATTGAGCGCG

[0069] TGCATGAGCTGGAACAGCAGAATAAAGTTCTGGAAGCAGAACTGCTG

[0070] GTTCTGCGTCAGAAACATAGCGAACCGAGCCGTTTCGTGCACTGTAT

[0071] GAACAGGAAATTCGTGATCTGCGTCTGGCAGCAGAAGATGCAACCAA

[0072] TGAAAAACAGGCACTGCAGGGTGAACGTGAAGGTCTGGAAGAAACCC

[0073] TGCGTAATCTGCAGGCACGTTATGAAGAAGAAGTTCTGAGCCGTGAA

[0074] GATGCAGAAGGTCGTCTGATGGAAGCACGTAAAGGTGCAGATGAAGC

[0075] AGCACTGGCACGTGCAGAACTGGAAAAACGTATTGATAGCCTGATGG

[0076] ATGAAATCAGCTTTCTGAAAAAAGTTCACGAGGAGGAGATTGCCGAA

[0077] CTGCAGGCACAGATTCAGTATGCACAGATTAGCGTTGAAATGGACGT

[0078] TACCAAACCGGATCTGAGCGCAGCACTGAAAGATATTCGTGCACAGT

[0079] ATGAAAAACTGGCCGCAAAAAATATGCAGAACGCCGAAGAATGGTTT

[0080] AAGAGCCGTTTTACCGTTCTGACCGAAAGCGCAGCAAAAAATACCGA

[0081] TGCAGTTCGTGCAGCAAAAGATGAAGTTAGCGAAAGCCGTCGTCTGC

[0082] TGAAAGCAAAAACCCTGGAAATTGAAGCATGTCGCGGTATGAATGAA

[0083] GCACTGGAAAAACAGCTGCAGGAACTGGAAGATAAACAGAATGCAG

[0084] ATATTAGCGCCATGCAGGATACCATTAATAAACTGGAAAACGAACTG

[0085] CGCACCACCAAAAGCGAAATGGCACGTTATCTGAAAGAATACCAGGA

[0086] CCTGCTGAATGTTAAAATGGCACTGGATATTGAGATCGCCGCATATCG

[0087] TAAACTGCTGGAGGGT

[0088] The sequence of SEQ ID NO: 5 is as follows:

[0089] CATATGCAGCTGCAGGATCTGAATGATCGTTTTGCAAGTTTTATTGAG

[0090] CGCGTGCATGAGCTGGAACAGCAGAATAAAGTTCTGGAAGCAGAACT

[0091] GCTGGTTCTGCGTCAGAAACATAGCGAACCGAGCCGTTTTCGTGCACT

[0092] GTATGAACAGGAAATTCGTGATCTGCGTCTGGCAGCAGAAGATGCAA

[0093] CCAATGAAAAACAGGCACTGCAGGGTGAACGTGAAGGTCTGGAAGA

[0094] AACCCTGCGTAATCTGCAGGCACGTTATGAAGAAGAAGTTCTGAGCC

[0095] GTGAAGATGCAGAAGGTCGTCTGATGGAAGCACGTAAAGGTGCAGAT

[0096] GAAGCAGCACTGGCACGTGCAGAACTGGAAAAACGTATTGATAGCCT

[0097] GATGGATGAAATCAGCTTTCTGAAAAAAGTTCACGAGGAGGAGATTG

[0098] CCGAACTGCAGGCACAGATTCAGTATGCACAGATTAGCGTTGAAATG

[0099] GACGTTACCAAACCGGATCTGAGCGCAGCACTGAAAGATATTCGTGC

[0100] ACAGTATGAAAAACTGGCCGCAAAAAATATGCAGAACGCCGAAGAAT

[0101] GGTTTAAGAGCCGTTTTACCGTTCTGACCGAAAGCGCAGCAAAAAAT

[0102] ACCGATGCAGTTCGTGCAGCAAAAGATGAAGTTAGCGAAAGCCGTCG

[0103] TCTGCTGAAAGCAAAAACCCTGGAAATTGAAGCATGTCGCGGTATGA

[0104] ATGAAGCACTGGAAAAACAGCTGCAGGAACTGGAAGATAAACAGAA

[0105] TGCAGATATTAGCGCCATGCAGGATACCATTAATAAACTGGAAAACG

[0106] AACTGCGCACCACCAAAAGCGAAATGGCACGTTATCTGAAAGAATAC

[0107] CAGGACCTGCTGAATGTTAAAATGGCACTGGATATTGAGATCGCCGC

[0108] ATATCGTAAACTGCTGGAGGGTGAATGACTCGAG

[0109] The present application provides an expression vector comprising the nucleic acid molecule described above. In some embodiments, the expression vector is a plasmid, a cosmid, a phage or a viral vector, preferably a plasmid.

[0110] For example, the nucleic acid molecules encoding the above-mentioned neurofilament light chain truncations can be cloned into suitable expression vectors, which can be any suitable recombinant expression vectors and can be used to transform or transfect any suitable host. Suitable vectors include those designed for propagation and amplification or for expression or for both, such as plasmids and viruses. In some embodiments, the expression vector is a plasmid.

[0111] In the present application, the expression vector may contain regulatory sequences (such as transcription and translation initiation and termination codons) that are specific to the type of host (e.g., bacteria, fungi, plants, or animals) into which the vector is to be introduced, taking into account whether the vector is DNA-based or RNA-based. The vector may also contain a non-natural promoter operably linked to the nucleotide sequence encoding the TCR. The promoter may be a non-viral promoter or a viral promoter, such as a cytomegalovirus (CMV) promoter, a SV40 promoter, a RSV promoter, and a promoter found in the long terminal repeat sequence of a mouse stem cell virus, and other promoters known to the skilled person are also contemplated.

[0112] The present application provides a host cell, which comprises the expression vector described above.

[0113] In the present application, the expression vector is transformed into a host cell to further express or clone in the host cell. In some embodiments, a method for preparing a neurofilament light chain truncate is provided, the method comprising culturing a host cell comprising a nucleic acid encoding a neurofilament light chain truncate as provided above under conditions suitable for expressing a neurofilament light chain truncate, and optionally recovering the neurofilament light chain truncate from the host cell (or host cell culture medium). In some embodiments, the host cell is a eukaryotic cell, a prokaryotic cell or a bacterial cell, preferably a prokaryotic cell, more preferably an Escherichia coli.

[0114] The host cell refers to a cell into which an exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include transformants and transformed cells, which include primary transformed cells and progeny derived therefrom, regardless of the number of passages. Progeny may not be completely identical to parent cells in nucleic acid content, but may contain mutations.

[0115] use

[0116] The present application provides the use of the above-mentioned neurofilament light chain truncate, the above-mentioned nucleic acid molecule, the above-mentioned expression vector or the above-mentioned host cell in preparing an antigen.

[0117] The present application provides the above-mentioned neurofilament light chain truncations, the above-mentioned nucleic acid molecules, the above-mentioned expression vectors or the above-mentioned host cells which can be used to prepare antigens, wherein the present application does not impose any restrictions on the method for preparing the antigens, and the antigens can be prepared according to conventional methods in the art, for example, protein purification methods such as affinity chromatography, ion exchange chromatography or molecular sieve chromatography can be used to prepare the antigens.

[0118] The present application provides the use of the above-mentioned neurofilament light chain truncated form, the above-mentioned nucleic acid molecule, the above-mentioned expression vector or the above-mentioned host cell in detecting Alzheimer's disease;

[0119] Or use in the preparation of an Alzheimer's disease diagnostic preparation or diagnostic kit.

[0120] The neurofilament light chain truncate described in the present application, the nucleic acid molecule described above, the expression vector described above or the host cell described above can be used for the early diagnosis of Alzheimer's disease. When used in the early diagnosis of Alzheimer's disease, the stability and yield of the marker NFL for early blood diagnosis of Alzheimer's disease are greatly improved, and the detection signal value is 18% higher than that of the commercial antigen, which provides an important key raw material for promoting the early blood diagnosis of Alzheimer's disease.

[0121] The present application also provides a product for detecting Alzheimer's disease, which comprises the above-mentioned neurofilament light chain truncated body, the above-mentioned nucleic acid molecule, the above-mentioned expression vector or the above-mentioned host cell. In some embodiments, the product further comprises a pharmaceutically acceptable excipient.

[0122] In the present application, there is no limitation on the auxiliary materials, which may be conventional auxiliary materials in the art, such as physiological saline.

[0123] The present application provides the use of the above-mentioned neurofilament light chain truncations, the above-mentioned nucleic acid molecules, the above-mentioned expression vectors or the above-mentioned host cells in preparing antibodies for preventing or treating Alzheimer's disease.

[0124] The present application provides an antibody, which is obtained by immunization using the above-mentioned neurofilament light chain truncated body, the above-mentioned nucleic acid molecule, the above-mentioned expression vector or the above-mentioned host cell.

[0125] The present application can use the above-mentioned neurofilament light chain truncations, the above-mentioned nucleic acid molecules, the above-mentioned expression vectors or the above-mentioned host cells to prepare antibodies. In the present application, there is no limitation on the method for preparing antibodies, and the antibodies can be prepared by conventional methods in the art, for example, hybridoma technology can be used to prepare antibodies.

[0126] Example

[0127] The present application provides a general and / or specific description of the materials and test methods used in the experiments. In the following examples, unless otherwise specified, % means wt%, i.e., weight percentage. The reagents or instruments used without indicating the manufacturer are all conventional reagent products that can be obtained commercially.

[0128] Example 1 Preparation of NFL truncated bodies and native NFL

[0129] The gene (SEQ ID NO: 5, which was prepared by conventional gene synthesis in the art) encoding the truncated form of the present application (SEQ ID NO: 3) was cloned into the expression vector pPGH vector, with restriction sites NdE I and Xho I. The constructed plasmid was transformed into competent E. coli BL21 (DE3), and the bacterial growth concentration OD 600 When the value is greater than 1.0, add 1mM IPTG to induce at 21℃ for 16h. Collect the cells under centrifugal conditions of 4000r / min for 20min, perform ultrasonic disruption, and collect the supernatant by low-temperature ultracentrifugation at 4℃, 16000g, 50min to obtain the target protein. Digest the target protein with PPase enzyme at room temperature for 4h, elute it from the filler with 25mM Tris, 150mM NaCl buffer, and obtain the target protein with high concentration and purity through anion exchange chromatography and molecular sieve. Figure 1 As shown in B.

[0130] The natural NFL gene (NCBI code: NP_006149.2) was cloned into the expression vector pPGH, with restriction sites: NdE I and Xhol I. The constructed plasmid was transformed into E. coli BL21 (DE3), and the bacterial growth concentration OD 600When the value was greater than 1.0, 1 mM IPTG was added for induction at 21°C for 16 h. The cells were collected under centrifugal conditions of 4000 r / min for 20 min, ultrasonically disrupted, and the precipitate was collected by low-temperature ultracentrifugation at 4°C and 16000 g for 50 min. The protein was extracted from the inclusion bodies using Lysis buffer (20 mM Tris pH 8.0, 150 mM NaCl, 0.2 mM PMSF, 10 mM DTT, 2 mM EDTA), Wash buffer 1 (1% Triton X-100, 20 mM Tris pH 8.0, 150 mM NaCl, 0.2 mM PMSF, 10 mM DTT, 2 mM EDTA), and Wash buffer 2 (0.5% Triton X-100, 20 mM Tris pH 8.0, 1.5 M NaCl, 0.2 mM PMSF, 10 mM DTT, 2 mM EDTA). Finally, the inclusion bodies were washed with Urea buffer (20 mM Tris pH 8.0, 150 mM NaCl, 8 M Urea, 0.1 mM PMSF, 10 mM DTT, 2 mM The protein was dissolved from the inclusion body by EDTA, centrifuged, and passed through a desalting column to quickly remove urea to obtain the target protein. The target protein was digested with PPase enzyme at room temperature for 4 hours, and the protein was further purified by molecular sieve to finally obtain a low-concentration and low-purity protein. Figure 1 As shown in A.

[0131] from Figure 1 As can be seen from B in the figure, the prepared NFL truncation has high purity and is numbered NFL-93-396.

[0132] Example 2 Detection of stability of NFL truncated body

[0133] The current market urgently needs soluble NFL proteins with stable performance and long-term storage. Therefore, the stability of NFL was studied. The NFL truncated body obtained in Example 1 was repeatedly frozen and thawed (frozen at -80°C and thawed in an ice bath). The protein concentration was detected by ultraviolet spectrophotometer to see whether it dropped significantly. The protein concentration is shown in Table 1. The protein was observed to see whether it precipitated. The results are shown in Table 1. Figure 2 shown.

[0134] Table 1

[0135]

[0136] From Table 1 and Figure 2 It can be seen that after freezing and thawing twice, the concentration of the NFL truncated protein did not change much and remained clear without precipitation.

[0137] Example 3 Detection of the Antigenic Effect of NFL Truncated Forms

[0138] 3 mL of the NFL truncated NFL-93-396 protein prepared in Example 1 at a concentration of 10.5 mg / mL was sent to a cooperative company, and conventional ELISA reagents (sandwich method) were used to detect its binding specificity and affinity performance with the antibody. The commercial Aibosheng antigen (Aibosheng recombinant protein product: Recombinant Human NEFL Protein, item number P00150PA) and the NFL-93-396 truncated body were gradiently diluted to a final concentration of 1280pg / mL, 640pg / mL, 320pg / mL, 160pg / mL, 80pg / mL and 40pg / mL, respectively. Add the ELISA plate coated with the capture antibody and incubate the reaction; repeat twice at each concentration, and add a negative control (0pg / mL) as a reference in the experiment. The conventional method in the art is used to use an ELISA reader to detect the ability of the colorimetric antibody to capture the antigen, thereby showing the affinity between the antigen and the antibody. The results are as follows: Figure 3 shown.

[0139] from Figure 3 It can be seen that compared with commercial antigens, the signal value of the NFL truncated antigen of the present application at the same concentration is about 20% higher, with excellent performance and suitable for reagent research and development.

[0140] Given that the content of NFL in the blood of early AD patients is low, it is not suitable to use the traditional ELISA method for detection. For this reason, Gewu Zhihe Company was commissioned to dilute the NFL truncated body NFL-93-396 and the commercialized Aids antigen with Simoa sample diluent to a final concentration of 100pg / mL, and operate according to the instructions of the Simoa kit (Quanterix Simoa NfL detection kit, #103400) to obtain the AEB value, and obtain the concentration of the NFL truncated body and the commercialized based on the standard curve. The results are shown in Table 2, where the standard curve is based on the standard sample in the Simoa kit and the instructions, and the curve obtained by fitting is shown in Table 2. Figure 4 As shown, the equation of the curve is:

[0141] in,

[0142] Y(x) is the AEB value;

[0143] A is 9.88E-003;

[0144] B is 9.81E-001;

[0145] C is 1.19E+004;

[0146] D is 3.35E+002.

[0147] Table 2

[0148] Experimental subjects Repetitions AEB average Concentration value Commercial antigens 2 0.3649 41.9056 NFL Truncated 2 0.8106 101.375

[0149] As can be seen from Table 2, the labeled concentration of the commercial NFL antigen is 2.4 times lower than the test result, which is a large difference; while the labeled concentration of the NFL antigen obtained in the present application is consistent with the test result, with excellent performance, indicating that the NFL antigen obtained in the present application is suitable for commercial reagent research and development purposes.

[0150] The above is only the preferred embodiment of the present application, and does not limit the present application in other forms. Any technician familiar with the profession may use the above disclosed technical content to change or modify it into an equivalent embodiment with equivalent changes. However, any simple modification, equivalent change and modification made to the above embodiment based on the technical essence of the present application without departing from the technical solution of the present application still falls within the protection scope of the technical solution of the present application.

Claims

1. A neurofilament light chain truncated form, wherein: The sequence of the neurofilament light chain truncate comprises the sequence shown in SEQ ID NO: 2 or 3 or the sequence shown in SEQ ID NO: 2 or 3. 2 . A nucleic acid molecule comprising a protein encoding the neurofilament light chain truncated form of claim 1 .

3. The nucleic acid molecule according to claim 1, wherein The nucleic acid molecule comprises a sequence as shown in any one of SEQ ID NOs: 4-5 or a sequence as shown in any one of SEQ ID NOs: 4-5. An expression vector comprising the nucleic acid molecule according to claim 2 or 3.

5. The expression vector according to claim 4, wherein The expression vector is a plasmid, a cosmid, a phage or a viral vector, preferably a plasmid.

6. A host cell comprising the expression vector according to claim 4 or 5; Preferably, the host cell is a eukaryotic cell, a prokaryotic cell or a bacterial cell, preferably a prokaryotic cell, and more preferably Escherichia coli.

7. Use of the neurofilament light chain truncated form of claim 1, the nucleic acid molecule of claim 2 or 3, the expression vector of claim 4 or 5, or the host cell of claim 6 in preparing an antigen.

8. Use of the neurofilament light chain truncated form of claim 1, the nucleic acid molecule of claim 2 or 3, the expression vector of claim 4 or 5, or the host cell of claim 6 in detecting Alzheimer's disease; Or use in the preparation of an Alzheimer's disease diagnostic preparation or diagnostic kit.

9. A preparation for detecting Alzheimer's disease, comprising the neurofilament light chain truncate of claim 1, the nucleic acid molecule of claim 2 or 3, the expression vector of claim 4 or 5, or the host cell of claim 6.

10. The preparation according to claim 9, further comprising a pharmaceutically acceptable excipient.

11. Use of the neurofilament light chain truncated form of claim 1, the nucleic acid molecule of claim 2 or 3, the expression vector of claim 4 or 5, or the host cell of claim 6 as an antigen in the preparation of antibodies for preventing or treating Alzheimer's disease. 12 . An antibody prepared by immunization using the neurofilament light chain truncated form of claim 1 , the nucleic acid molecule of claim 2 or 3 , the expression vector of claim 4 or 5 , or the host cell of claim 6 .